NervGen Pharma Corp.
NGENF · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $4,444 | $2,711 | $3,148 | $4,589 |
| G&A Expenses | $1,726 | $3,758 | $2,887 | $2,215 |
| SG&A Expenses | $1,726 | $3,758 | $2,887 | $2,215 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $2 |
| Operating Expenses | $6,171 | $6,469 | $6,035 | $6,806 |
| Operating Income | -$6,171 | -$6,469 | -$6,035 | $0 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $2,015 | -$2,635 | $2,087 | -$8,609 |
| Pre-Tax Income | -$4,156 | -$9,104 | -$3,948 | -$8,609 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$4,156 | -$9,104 | -$3,948 | -$8,609 |
| % Margin | – | – | – | – |
| EPS | -0.06 | -0.13 | -0.056 | -0.12 |
| % Growth | 53.8% | -132.6% | 53.4% | – |
| EPS Diluted | -0.06 | -0.13 | -0.056 | -0.12 |
| Weighted Avg Shares Out | 73,163 | 71,957 | 70,667 | 70,071 |
| Weighted Avg Shares Out Dil | 73,163 | 71,957 | 70,667 | 70,071 |
| Supplemental Information | – | – | – | – |
| Interest Income | $77 | $87 | $108 | $171 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $14 | $14 | $14 | $16 |
| EBITDA | -$6,157 | -$6,455 | -$6,021 | -$6,790 |
| % Margin | – | – | – | – |